Skip to main content
All lobbying filings

FERRING PHARMACEUTICALS, INC.

Lobbying for FERRING PHARMACEUTICALS, INC.

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $290,000.00 expenses · posted Jan 15, 2026

Official filing document

 Bills named in this filing 8
  • HR 1670
    Family Building FEHB Fairness Act
  • S 797
    Family Building FEHB Fairness Act
  • HR 220
    Veterans Infertility Treatment Act of 2025
  • S 2296
    National Defense Authorization Act for Fiscal Year 2026
  • HR 3838
    Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
  • HR 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • HR 1878
    IVF Access and Affordability Act
  • HR 4639
    Infertility Treatment Affordability Act of 2025
 Lobbying activity 2
Health Issues

Issues related to fertility treatment and coverage (no bill); issues related to federal employee health care coverage (Family Building FEHB Fairness Act, H.R. 1670 / S. 797), issues related to veterans health coverage (Veterans Infertility Treatment Act, H.R. 220 / no Senate bill), issues related to infertility coverage for members of the military included in the National Defense Authorization Act (S. 2296, Sec. 705 / H.R. 3838, Sec. 703), issues related to access to cancer treatments (Protecting Patient Access to Cancer and Complex Therapies Act, H.R. 4299 / no Senate bill).

Taxation/Internal Revenue Code

Issues related to establishing a tax credit for fertility treatments (IVF Access and Affordability Act, H.R. 1878 / no Senate bill; Infertility Treatment Affordability Act, H.R.4639 / no Senate bill).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem